Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-05-20 Purchase | 2026-05-21 4:31 pm | Entrada Therapeutics Inc. | TRDA | Zeiher Bernhardt G Director | 5,000 | $5.8632 | $29,316 | 5,000 (Indirect) | View |
| 2026-05-04 Sale | 2026-05-04 7:25 pm | Entrada Therapeutics Inc. | TRDA | Sethuraman Natarajan President, Research & Develop. | 25,907 | $15.39 | $398,810 | 216,317 (Direct) | View |
| 2026-05-04 Sale | 2026-05-04 7:24 pm | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 15,000 | $15.33 | $229,953 | 248,419 (Direct) | View |
| 2026-04-01 Sale | 2026-04-02 4:39 pm | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 2,500 | $12.95 | $32,375 | 119,010 (Direct) | View |
| 2026-03-09 Sale | 2026-03-11 4:35 pm | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 15,010 | $13.04 | $195,771 | 198,588 (Direct) | View |
| 2026-03-09 Sale | 2026-03-11 4:34 pm | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 16,477 | $13.01 | $214,379 | 121,510 (Direct) | View |
| 2026-03-04 Sale | 2026-03-06 4:36 pm | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 7,988 | $12.25 | $97,892 | 137,987 (Direct) | View |
| 2025-11-21 Sale | 2025-11-24 4:30 pm | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 8,910 | $9.9811 | $88,932 | 110,026 (Direct) | View |
| 2025-11-20 Purchase | 2025-11-24 4:09 pm | Entrada Therapeutics Inc. | TRDA | BAKER BROS. ADVISORS LP Baker Bros. Advisors (GP) LLC BAKER FELIX BAKER JULIAN 10% Owner | 28,867 | $9.0708 | $261,846 | 4,691,392 (Indirect) | View |
| 2025-11-14 Sale | 2025-11-18 4:36 pm | Entrada Therapeutics Inc. | TRDA | PARMAR KUSH Director 10% Owner | 200,000 | $8.8 | $1,760,000 | 4,056,379 (Indirect) | View |
| 2025-11-14 Sale | 2025-11-18 4:34 pm | Entrada Therapeutics Inc. | TRDA | 5AM Ventures V L.P. 5AM Partners V LLC 5AM Opportunities I L.P. 5AM Opportunities I (GP) LLC ROCKLAGE SCOTT M Schwab Andrew J. 10% Owner | 200,000 | $8.8 | $1,760,000 | 4,056,379 (Indirect Direct) | View |
| 2025-11-10 Purchase | 2025-11-12 5:34 pm | Entrada Therapeutics Inc. | TRDA | BAKER BROS. ADVISORS LP Baker Bros. Advisors (GP) LLC BAKER FELIX BAKER JULIAN 10% Owner | 178,044 | $7.5969 | $1,352,587 | 4,664,924 (Indirect) | View |
| 2025-07-09 Sale | 2025-07-11 5:27 pm | Entrada Therapeutics Inc. | TRDA | PARMAR KUSH Director 10% Owner | 27,000 | $7.502 | $202,554 | 1,093,313 (Indirect) | View |
| 2025-07-09 Sale | 2025-07-11 5:25 pm | Entrada Therapeutics Inc. | TRDA | 5AM Ventures V L.P. 5AM Partners V LLC 5AM Opportunities I L.P. 5AM Opportunities I (GP) LLC ROCKLAGE SCOTT M Schwab Andrew J. 10% Owner | 27,000 | $7.502 | $202,554 | 4,256,379 (Indirect Direct) | View |
| 2025-06-27 Sale | 2025-07-01 8:33 pm | Entrada Therapeutics Inc. | TRDA | PARMAR KUSH Director 10% Owner | 125,000 | $6.9331 | $866,633 | 1,100,248 (Indirect) | View |
| 2025-06-27 Sale | 2025-07-01 8:32 pm | Entrada Therapeutics Inc. | TRDA | 5AM Ventures V L.P. 5AM Partners V LLC 5AM Opportunities I L.P. 5AM Opportunities I (GP) LLC ROCKLAGE SCOTT M Schwab Andrew J. 10% Owner | 125,000 | $6.9331 | $866,633 | 4,283,379 (Indirect Direct) | View |
| 2024-05-13 Purchase(A) | 2025-06-18 4:32 pm | Entrada Therapeutics Inc. | TRDA | KIM PETER S Director | 50,000 | $14.63 | $731,683 | 117,412 (Direct) | View |
| 2025-03-17 Sale | 2025-03-19 4:32 pm | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 1,784 | $10.67 | $19,035 | 109,536 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-06-10 Option Award | 2026-06-12 5:34 pm | N/A 2036-06-10 | Entrada Therapeutics Inc. | TRDA | PARMAR KUSH Director 10% Owner | 19,000 | $0 | 19,000 (Direct) | View |
| 2026-06-10 Option Award | 2026-06-12 5:17 pm | N/A 2036-06-10 | Entrada Therapeutics Inc. | TRDA | KIM PETER S Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2026-06-10 Option Award | 2026-06-12 5:16 pm | N/A 2036-06-10 | Entrada Therapeutics Inc. | TRDA | Chapman Gina Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2026-06-10 Option Award | 2026-06-12 5:05 pm | N/A 2036-06-10 | Entrada Therapeutics Inc. | TRDA | Radhakrishnan Maha Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2026-06-10 Option Award | 2026-06-12 5:01 pm | N/A 2036-06-10 | Entrada Therapeutics Inc. | TRDA | Thistle Mary Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2026-06-10 Option Award | 2026-06-12 4:52 pm | N/A 2036-06-10 | Entrada Therapeutics Inc. | TRDA | Zeiher Bernhardt G Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2026-05-04 Exercise | 2026-05-04 7:24 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 15,000 | $1.74 | 248,419 (Direct) | View |
| 2026-05-04 Exercise | 2026-05-04 7:24 pm | N/A 2029-12-10 | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 15,000 | $0 | 248,419 (Direct) | View |
| 2026-03-03 Tax Withholding | 2026-03-03 6:21 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Doshi Dipal CEO | 19,181 | $11.76 | 734,014 (Direct) | View |
| 2026-03-02 Tax Withholding | 2026-03-03 6:21 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Doshi Dipal CEO | 9,869 | $11.66 | 734,014 (Direct) | View |
| 2026-03-01 Option Award | 2026-03-03 6:21 pm | N/A 2036-03-01 | Entrada Therapeutics Inc. | TRDA | Doshi Dipal CEO | 347,400 | $0 | 734,014 (Direct) | View |
| 2026-03-03 Tax Withholding | 2026-03-03 6:20 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 5,712 | $11.76 | 212,575 (Direct) | View |
| 2026-03-02 Tax Withholding | 2026-03-03 6:20 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 2,939 | $11.66 | 212,575 (Direct) | View |
| 2026-03-01 Option Award | 2026-03-03 6:20 pm | N/A 2036-03-01 | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 111,200 | $0 | 212,575 (Direct) | View |
| 2026-03-03 Tax Withholding | 2026-03-03 6:19 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 14,038 | $11.76 | 296,798 (Direct) | View |
| 2026-03-02 Tax Withholding | 2026-03-03 6:19 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 7,223 | $11.66 | 296,798 (Direct) | View |
| 2026-03-01 Option Award | 2026-03-03 6:19 pm | N/A 2036-03-01 | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 139,000 | $0 | 296,798 (Direct) | View |
| 2026-03-03 Tax Withholding | 2026-03-03 6:18 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Sethuraman Natarajan President, Research & Develop. | 7,577 | $11.76 | 325,424 (Direct) | View |
| 2026-03-02 Tax Withholding | 2026-03-03 6:18 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Sethuraman Natarajan President, Research & Develop. | 3,898 | $11.66 | 325,424 (Direct) | View |
| 2026-03-01 Option Award | 2026-03-03 6:18 pm | N/A 2036-03-01 | Entrada Therapeutics Inc. | TRDA | Sethuraman Natarajan President, Research & Develop. | 139,000 | $0 | 325,424 (Direct) | View |
| 2025-09-02 Tax Withholding | 2025-09-04 5:04 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Doshi Dipal CEO | 8,723 | $5.4302 | 415,664 (Direct) | View |
| 2025-09-02 Tax Withholding | 2025-09-04 5:03 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Dowden Nathan J President & COO | 1,746 | $5.4302 | 179,059 (Direct) | View |
| 2025-09-02 Tax Withholding | 2025-09-04 5:03 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | Sethuraman Natarajan President, Research & Develop. | 1,760 | $5.4302 | 197,899 (Direct) | View |
| 2025-09-02 Tax Withholding | 2025-09-04 5:02 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 1,734 | $5.4302 | 118,936 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 08:10 am | N/A 2035-06-11 | Entrada Therapeutics Inc. | TRDA | PARMAR KUSH Director 10% Owner | 19,000 | $0 | 19,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 08:08 am | N/A 2035-06-11 | Entrada Therapeutics Inc. | TRDA | KIM PETER S Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 08:07 am | N/A 2035-06-11 | Entrada Therapeutics Inc. | TRDA | Thistle Mary Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 08:06 am | N/A 2035-06-11 | Entrada Therapeutics Inc. | TRDA | Zeiher Bernhardt G Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-12 08:04 am | N/A 2035-06-11 | Entrada Therapeutics Inc. | TRDA | Chapman Gina Director | 19,000 | $0 | 19,000 (Direct) | View |
| 2025-06-01 Option Award | 2025-06-03 08:13 am | 2025-06-01 2035-06-01 | Entrada Therapeutics Inc. | TRDA | Radhakrishnan Maha Director | 38,000 | $0 | 38,000 (Direct) | View |
| 2025-04-03 Exercise | 2025-04-04 4:34 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 11,134 | $2.1 | 140,693 (Direct) | View |
| 2025-04-03 Exercise | 2025-04-04 4:34 pm | N/A 2030-11-10 | Entrada Therapeutics Inc. | TRDA | WENTWORTH KORY JAMES Chief Financial Officer | 11,134 | $0 | 140,693 (Direct) | View |